Table 2 Cox proportional hazard analyses of adverse long-term event outcomes
From: The role of Asprosin in patients with dilated cardiomyopathy
Variable | Univariate analysis | |
|---|---|---|
HR (95% CI) | P value | |
Asprosin (< 120 vs ≥120 ng/mL) | 7.94 (1.88–33.50) | 0.005 |
Age, y | 0.93 (0.87–1.00) | 0.04 |
Female gender, n (%) | 0.83 (0.14–4.8) | 0.83 |
Body mass index, kg/m2 | 0.09 (−0.06–0.23) | 0.24 |
Hypertension, n (%) | 1.26 (0.34–4.65) | 0.73 |
Diabetes mellitus, n (%) | 0.08 (−1.30–1.46) | 0.91 |
NYHA class III or IV, n (%) | 0.70 (0.18–2.67) | 0.60 |
Atrial fibrillation, n (%) | 1.26 (0.36–4.34) | 0.72 |
LV mass index, g/m2 | 1.00 (0.99–1.01) | 0.793 |
LV end-diastolic volume index, mL/m2 | 1.00 (0.99–1.01) | 0.28 |
LV ejection fraction, % | 0.92 (0.84–0.99) | 0.03 |
Mitral E/A ratio | 1.33 (0.46–3.86) | 0.60 |
BNP, pg/mL | 1.00 (0.99–1.00) | 0.20 |
eGFR, mL/min/1.73 m2 | 1.00 (0.98–1.03) | 0.79 |
Creatinine, mg/dL | 0.66 (0.25–1.76) | 0.40 |
Cholesterol, mg/dL | 0.97 (0.95–0.99) | 0.007 |
Sugar, mg/dL | 0.98 (0.95–1.02) | 0.32 |